Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy

Gastric adenocarcinoma (GAC) is the third most common cause of cancer-related deaths worldwide. Combination chemotherapy remains the standard treatment for advanced GAC. Liposomal irinotecan (nal-IRI) has improved pharmacokinetics (PK) and drug biodistribution compared with irinotecan (IRI, CPT-11)....

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Niranjan, Schwarz, Margaret A., Zhang, Changhua, Klinz, Stephan G., Meyer-Losic, Florence, Beaufils, Benjamin, Thiagalingam, Arunthathi, Schwarz, Roderich E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377761/
https://www.ncbi.nlm.nih.gov/pubmed/35500018
http://dx.doi.org/10.1158/1535-7163.MCT-21-0860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377761/
https://www.ncbi.nlm.nih.gov/pubmed/35500018
http://dx.doi.org/10.1158/1535-7163.MCT-21-0860

Ejemplares similares